MarketResearchReports.Biz include new market research report "China PTCA Balloon Market Investment Report, 2014-2016" to its huge collection of research reports.
Albany, NY -- (SBWIRE) -- 10/09/2014 -- PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. Therefore, the development of PTCA balloon industry is closely related to that of PCI.
To Read Complete Report with Toc:
As national economy develops and people’s living standard improves, the number of patients receiving PCI has been on the rise year by year, and totaled 454,505 cases in China in 2013, up 16.9% from a year earlier. Demand for PTCA balloon during the same period reached 1.186 million sets, rising by 13.8% on a year-on-year basis.
Despite year-on-year growth in the number of PCI cases in China, the penetration is still very low. In 2013, 309.42 per 1 million were people receiving PCI treatment in China, compared with 1800 cases in the United States, showing a vast space for development of the Chinese PCI market and a bright future for PTCA balloon industry. It is expected that China’s demand for PTCA balloon will hit 1.824 million sets by 2016.
Browse Full Report With Toc:
At present, the Chinese PTCA balloon market is still dominated by foreign companies, such as Medtronic, Abbott, Boston Scientific, Goodman, Terumo, etc. However, local Chinese PTCA balloon companies are improving their competitiveness, with overall market share rising to about 40% in 2013 as opposed to 20% in 2009.
Local Chinese PTCA balloon companies include Lepu Medical, MicroPort, JW Medical, Yinyi, Neich Medical (Shenzhen), Synexmed, Sino Medical and Demax Medical, of which Lepu Medical, MicroPort, Neich Medical (Shenzhen) and Sino Medical manufacture both PTCA balloon catheter for delivering coronary stent and PTCA balloon, JW Medical manufactures only PTCA balloon for delivering coronary stent, and Demax Medical produces only PTCA balloon.
MicroPort is a bellwether in the Chinese coronary stent system market. On Jan. 20, 2014, MicroPort announced that it would acquire drug-eluting stent-related assets of Cordis under Johnson & Johnson. After the acquisition is completed, MicroPort’s share in drug-eluting stent market will rise by over 10%. This will also promote company’s business development of PTCA balloon for delivering coronary stent. MicroPort now can manufacture more than 200,000 sets of PTCA balloon annually.
Click Here To Download Detail Report:
Lepu Medical is a leading player in China PTCA balloon industry. The company now has PTCA balloon dilatation catheter capacity of 100,000 sets and coronary stent delivery system capacity of 170,000 sets.